Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Stromedix, Inc.
Information provided by (Responsible Party):
Stromedix, Inc. Identifier:
First received: June 3, 2011
Last updated: May 14, 2013
Last verified: May 2013

This is a multi-center, randomized, double-blind, placebo-controlled, multiple dose, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and impact on BAL and peripheral blood biomarkers of STX-100 in patients with IPF. Approximately 32 patients will be enrolled into 4 sequential ascending dose cohorts. Each cohort will include 8 patients randomized to receive either STX-100 (6 patients) or placebo (2 patients). Additional patients may be enrolled if deemed appropriate by the Data Safety Monitoring Board (DSMB).

Condition Intervention Phase
Idiopathic Pulmonary Fibrosis (IPF)
Drug: STX-100
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose-Escalation Study of STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Resource links provided by NLM:

Further study details as provided by Stromedix, Inc.:

Primary Outcome Measures:
  • Incidence and severity of adverse events [ Time Frame: Weekly assessment over 24 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Lab tests (hematology, serum chemistry, and urinalysis) [ Time Frame: Screening; Dosing days 1, 8, 15, 29, 43, and 50; Follow up days 3, 8, 29, 57, and 85 ] [ Designated as safety issue: Yes ]
  • Percent change in lung function: forced (expiratory) vital capacity (FVC), forced expiratory volume over one second (FEV1), total lung capacity (TLC), and carbon monoxide diffusion capacity (DLCO) [ Time Frame: Baseline, 4 weeks and 8 weeks ] [ Designated as safety issue: Yes ]
  • Change in radiographic evidence of IPF as measured by high resolution computed tomography (HRCT) [ Time Frame: Baseline, week 8 ] [ Designated as safety issue: Yes ]
  • Change in biomarkers isolated from bronchoalveolar lavage (BAL) [ Time Frame: Baseline, week 8 ] [ Designated as safety issue: Yes ]
  • Incidence of antibodies to STX-100 [ Time Frame: Baseline, follow up days 29 and 85 ] [ Designated as safety issue: Yes ]
  • Serum half-life of STX-100 [ Time Frame: Following the final dose of STX 100 at day 50 through day 85 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 32
Study Start Date: May 2012
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: STX-100
Active treatment with study drug
Drug: STX-100
Subcutaneous (SC) delivery of 8 consecutive weekly doses
Placebo Comparator: Placebo Drug: Placebo
Subcutaneous (SC) delivery of 8 consecutive weekly doses


Ages Eligible for Study:   18 Years to 84 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Consenting male or female patients, 50 to 84 years old, inclusive. Patients 18 to 49 years of age are eligible if they have a histopathologic diagnosis of usual interstitial pneumonia (UIP) based upon a surgical lung biopsy in the appropriate clinical setting, and meet all other inclusion/exclusion criteria.
  2. Clinical features consistent with IPF prior to screening (based on the ATS/ERS/JRS/ALAT consensus criteria for the diagnosis of IPF).
  3. FVC ≥ 50% of predicted value.
  4. DLco (corrected for hemoglobin) ≥ 35% predicted value.
  5. Oxygen saturation > 90% by pulse oximetry while breathing ambient air at rest.
  6. Residual volume ≤ 120% predicted value.
  7. Ratio of FEV1 to FVC ≥ 0.65 after the use of a bronchodilator.
  8. Other known causes of interstitial lung disease have been excluded (e.g., drug toxicities, environmental exposures, connective tissue diseases).
  9. HRCT image fulfills the criteria for 'UIP pattern'.
  10. If the HRCT image does not fulfill the criteria for 'UIP pattern' a surgical lung biopsy is necessary for the diagnosis of IPF.
  11. Adequate bone marrow and liver function.
  12. Patient has a life expectancy of at least 12 months.

Exclusion Criteria:

  1. Findings that are diagnostic of a condition other than UIP on surgical lung biopsy, HRCT imaging, transbronchial lung biopsy, or bronchoalveolar lavage (BAL).
  2. Currently receiving high dose corticosteroid, cytotoxic (e.g., chlorambucil, azathioprine, cyclophosphamide, methotrexate), anti-fibrotic (e.g., pirfenidone), vasodilator therapy for pulmonary hypertension (e.g., bosentan), unapproved (e.g., INF-γ, penicillamine, cyclosporine, mycophenolate, Nacetylcysteine), and/or investigational therapy for IPF or administration of such therapeutics within 4 weeks of initial screening. A current dose of ≤ 15 mg/day of prednisone or its equivalent is acceptable if it is anticipated the dose will remain stable during the study.
  3. History of malignancy, including carcinoma during the preceding 5 years.
  4. Significant cardiac disease (e.g., New York Heart Association [NYHA] Class 3 or 4; myocardial infarction within the past 6 months; unstable angina; coronary angioplasty or coronary artery bypass graft [CABG] within the past 6 months; or uncontrolled atrial or ventricular cardiac arrhythmias).
  5. Serious local infection or systemic infection within 3 months prior to screening.
  6. Positive test for HBsAg, HCV antibody, or HIV antibody at screening.
  7. Treatment with another investigational drug, investigational device, or approved therapy for investigational use within 4 weeks of initial screening.
  8. Currently listed and/or anticipated to be listed for lung transplantation within the next 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01371305

Contact: Emily Graham 734-369-3873
Contact: Kris Hermanson 608-310-4086

United States, California
University of California-San Francisco Recruiting
San Francisco, California, United States, 94143
Principal Investigator: Jeff Golden, MD         
Stanford University Medical Center Recruiting
Stanford, California, United States, 94305
Principal Investigator: Glenn Rosen, MD         
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Principal Investigator: Mark Brantly, MD         
University of Miami Recruiting
Miami, Florida, United States, 33136
Principal Investigator: Marilyn K Glassberg, MD         
United States, Georgia
Emory University School of Medicine Recruiting
Atlanta, Georgia, United States, 30322
Principal Investigator: Srihari Veeraraghavan, MD         
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637
Principal Investigator: Imre Noth, MD         
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Principal Investigator: Joseph Zibrak, MD         
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Principal Investigator: Hilary J Goldberg, MD         
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Principal Investigator: Leo C Ginns, MD         
United States, New Hampshire
Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Principal Investigator: Richard I Enelow, MD         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Principal Investigator: Daniel Culver, DO         
United States, Pennsylvania
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Principal Investigator: Kevin Gibson, MD         
United States, Tennessee
Vanderbilt University Medical Center Recruiting
Nashville, Tennessee, United States, 37232
Principal Investigator: Lisa Lancaster, MD         
United States, Texas
Baylor College of Medicine and The Methodist Hospital Recruiting
Houston, Texas, United States, 77030
Principal Investigator: Adaani Frost, MD         
Sponsors and Collaborators
Stromedix, Inc.
Study Director: Brad Maroni, MD Stromedix, Inc.
  More Information

No publications provided

Responsible Party: Stromedix, Inc. Identifier: NCT01371305     History of Changes
Other Study ID Numbers: STX-003
Study First Received: June 3, 2011
Last Updated: May 14, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Lung Diseases
Lung Diseases, Interstitial
Pathologic Processes
Respiratory Tract Diseases processed this record on November 20, 2014